Developer docs
API playgroundTry for free, no card

Search company profiles

Lucane Pharma

Full company profile

uuid0027yq1

Namestring
Lucane Pharma
Legal namestring
Eurocept International B.V.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Lucane Pharma is a Paris-headquartered pharmaceutical company founded in 2009 that develops and commercializes medicinal products for rare disorders. It operates as a wholly-owned subsidiary of Eurocept Pharmaceuticals Holding, a Dutch private holding founded in 2001. The company is led by CEO Thomas Calis and operates alongside sister entities Lucane SAS, Eurocept B.V., and Eurocept Xytron Medical B.V.

Lucane's commercial portfolio comprises five reformulated niche molecules: Xaluprine (mercaptopurine oral suspension for acute lymphocytic leukemia), Ucedane (carglumic acid for urea cycle disorders), Pheburane (sodium phenylbutyrate for urea cycle disorders, in granules and oral solution), Granupas (para-aminosalicylic acid for multidrug-resistant tuberculosis), and Amsalyo (amsacrine). Four EMA marketing authorizations have been secured (2013, 2014, 2017, 2023), plus approvals in Turkey and Canada, and the company is developing nine additional products targeting very rare disorders. The technical differentiator is reformulation and age-appropriate presentation design — notably for neonatal and pediatric dosing — rather than novel molecule discovery.

The business model is direct pharmaceutical commercialization in six European markets (France, Turkey, Spain, Italy, UK, Benelux) combined with distributor partnerships for global reach. Lucane deploys a specialized scientific sales team that engages the small number of physicians treating each rare condition, and distributes directly to hospitals and retail pharmacies to guarantee supply for patient populations as small as one or two per country. Pricing is negotiated with national health authorities rather than publicly disclosed. The company is actively seeking additional distribution partners worldwide, indicating a distributor-led go-to-market for territories outside its direct-presence footprint.

Short descriptiontext

Lucane Pharma is a French pharmaceutical subsidiary of Eurocept Pharmaceuticals Holding that develops and commercializes reformulated medicines for rare disorders, serving patients with urea cycle disorders, leukemia, and multidrug-resistant tuberculosis across Europe, Turkey, and global distributor markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease medicines, orphan drug development, specialty pharmaceuticals, pharmaceutical distribution, medicinal product commercialization
Industry3 codes
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Orphan Disease Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

Lucane Pharma generates revenue through the sale of proprietary and licensed pharmaceutical products targeting rare diseases. Products are sold directly through their presence in France, Turkey, Spain, Italy, United Kingdom, and Benelux, as well as through distributors globally.

lucanepharma.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lucane Pharma develops, registers, and commercializes proprietary and licensed pharmaceutical products targeting rare disorders (orphan drugs). Its marketed portfolio includes Xaluprine for acute lymphocytic leukemia, Ucedane for urea cycle disorders (carglumic acid), Pheburane (sodium phenylbutyrate) for urea cycle disorders in granules and oral solution forms, Granupas for multidrug-resistant tuberculosis, and Amsalyo (amsacrine). The company improves formulations of existing molecules, develops new presentations for specific age groups (neonates, children, adults), and sells directly to hospitals and pharmacies across France, Turkey, Spain, Italy, the UK, and Benelux while using distributors in other global markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Lucane Pharma is a pharmaceutical company specializing in the development and commercialization of medicines for rare diseases. The company operates as part of Eurocept Pharmaceuticals Holding and offers a portfolio of niche medicines including Xaluprine (mercaptopurine oral suspension for acute lymphocytic leukemia), Ucedane (carglumic acid for urea cycle disorders), Pheburane (sodium phenylbutyrate for urea cycle disorders), Granupas (para-aminosalicylic acid for multidrug-resistant tuberculosis), and Amsalyo (amsacrine for infusion). Lucane Pharma improves formulations of existing products, develops new presentations fulfilling specific needs, and improves global accessibility of its products through direct presence in France, Turkey, Spain, Italy, United Kingdom, Benelux, and via distributors globally. The company is actively engaged in the development of 9 products for very rare disorders.

Product and service5 records
1Xaluprine
CategoryOrphan oncology pharmaceutical product
Description

Brand-name mercaptopurine oral suspension indicated for the treatment of acute lymphocytic leukemia. Belongs to the cytotoxics (chemotherapy) group that works by preventing cancer cells from multiplying, and was specifically designed to facilitate dosing in specific age groups.

2Ucedane
CategoryOrphan metabolic disease pharmaceutical product
Description

An alternative version of carglumic acid with notable differences from the original, used in the treatment of urea cycle disorders (UCDs).

3Pheburane
CategoryOrphan metabolic disease pharmaceutical product
Description

An alternative version of sodium phenylbutyrate with notable differences from the original, used in the treatment of urea cycle disorders (UCDs). Available in granules and oral solution forms.

4Granupas
CategoryOrphan infectious disease pharmaceutical product
Description

Brand-name para-aminosalicylic acid, a proven molecule used as part of an appropriate combination regimen for multidrug-resistant tuberculosis, which is rare in the EU today.

5Amsalyo
CategoryOrphan oncology pharmaceutical product
Description

Brand-name amsacrine powder for solution for infusion. Belongs to the cytotoxics (chemotherapy) group that works by preventing cancer cells from multiplying.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical division of Recordati focused on rare diseases with direct presence across Europe; directly comparable in commercial model, therapeutic focus (rare metabolic and endocrine disorders), and EMA-anchored portfolio strategy.

TypeDirect peer
Description

Global rare-disease biotech with multiple EMA-approved products for very rare metabolic disorders; comparable in orphan-drug commercial focus and concentration on small-population specialty therapeutics.

TypeDirect peer
Description

Public rare-disease specialty pharma headquartered in Europe, with a portfolio centered on niche metabolic, hematology, and immunology indications — directly comparable in orphan-drug strategy, EU regulatory focus, and reformulation/repositioning approach.

TypeDirect peer
Description

European specialty pharma arm of Kyowa Kirin focused on rare diseases and specialty therapeutics with strong EU commercialization; comparable in orphan-drug portfolio strategy and direct presence in multiple EU countries.

TypeBroad incumbent
Description

European-headquartered specialty pharma with rare-disease and neonatology franchises; comparable in EU direct commercialization, focus on underserved pediatric/rare populations, and reformulation of established molecules.

TypeDirect peer
Description

Clinical-stage and commercial rare-disease biotech focused on metabolic and rare genetic disorders; comparable in orphan-drug regulatory pathway, small patient populations, and reformulation/repositioning of therapies.

TypeDirect peer
Description

Specialty pharma with a portfolio spanning rare oncology, neurology, and sleep disorders; comparable in niche-indication focus, EMA presence, and reformulation of existing molecules (e.g., oral suspension presentations).

8Orphan Europe (Recordati Group)
TypeDirect peer
Description

European rare-disease pharma (now part of Recordati) that develops and commercializes treatments for very rare disorders; highly comparable in mission, EMA orphan-drug portfolio, and small-population disease focus.

TypeBroad incumbent
Description

Pioneering rare-disease franchise within Sanofi with deep expertise in metabolic disorders (e.g., enzyme replacement therapies); comparable in therapeutic area overlap (UCDs, metabolic conditions) but at global mega-cap scale.

TypeBroad incumbent
Description

Established global rare-disease franchise within AstraZeneca, with multiple EMA-approved orphan drugs and direct European commercialization — overlaps in therapeutic areas and regulatory pathways, but operates at vastly larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucane Pharma

Orphan Disease Pharmaceuticalslucanepharma.com

Lucane Pharma is a French pharmaceutical subsidiary of Eurocept Pharmaceuticals Holding that develops and commercializes reformulated medicines for rare disorders, serving patients with urea cycle disorders, leukemia, and multidrug-resistant tuberculosis across Europe, Turkey, and global distributor markets.

What Lucane Pharma does

Lucane Pharma is a Paris-headquartered pharmaceutical company founded in 2009 that develops and commercializes medicinal products for rare disorders. It operates as a wholly-owned subsidiary of Eurocept Pharmaceuticals Holding, a Dutch private holding founded in 2001. The company is led by CEO Thomas Calis and operates alongside sister entities Lucane SAS, Eurocept B.V., and Eurocept Xytron Medical B.V.

Lucane's commercial portfolio comprises five reformulated niche molecules: Xaluprine (mercaptopurine oral suspension for acute lymphocytic leukemia), Ucedane (carglumic acid for urea cycle disorders), Pheburane (sodium phenylbutyrate for urea cycle disorders, in granules and oral solution), Granupas (para-aminosalicylic acid for multidrug-resistant tuberculosis), and Amsalyo (amsacrine). Four EMA marketing authorizations have been secured (2013, 2014, 2017, 2023), plus approvals in Turkey and Canada, and the company is developing nine additional products targeting very rare disorders. The technical differentiator is reformulation and age-appropriate presentation design — notably for neonatal and pediatric dosing — rather than novel molecule discovery.

The business model is direct pharmaceutical commercialization in six European markets (France, Turkey, Spain, Italy, UK, Benelux) combined with distributor partnerships for global reach. Lucane deploys a specialized scientific sales team that engages the small number of physicians treating each rare condition, and distributes directly to hospitals and retail pharmacies to guarantee supply for patient populations as small as one or two per country. Pricing is negotiated with national health authorities rather than publicly disclosed. The company is actively seeking additional distribution partners worldwide, indicating a distributor-led go-to-market for territories outside its direct-presence footprint.

Lucane Pharma firmographics

Firmographics
Name
Lucane Pharma
Legal name
Eurocept International B.V.
Website
https://lucanepharma.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Lucane Pharma is a French pharmaceutical subsidiary of Eurocept Pharmaceuticals Holding that develops and commercializes reformulated medicines for rare disorders, serving patients with urea cycle disorders, leukemia, and multidrug-resistant tuberculosis across Europe, Turkey, and global distributor markets.
Ownership category
akta.pro rank

Lucane Pharma industry classification

Industry
Product category
Orphan Disease Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Rare disease medicines
  • Orphan drug development
  • Specialty pharmaceuticals
  • Pharmaceutical distribution
  • Medicinal product commercialization

Where Lucane Pharma is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Lucane Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical product sales: Lucane Pharma generates revenue through the sale of proprietary and licensed pharmaceutical products targeting rare diseases. Products are sold directly through their presence in France, Turkey, Spain, Italy, United Kingdom, and Benelux, as well as through distributors globally.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Lucane Pharma product offering

Product offering

Core offering

Lucane Pharma develops, registers, and commercializes proprietary and licensed pharmaceutical products targeting rare disorders (orphan drugs). Its marketed portfolio includes Xaluprine for acute lymphocytic leukemia, Ucedane for urea cycle disorders (carglumic acid), Pheburane (sodium phenylbutyrate) for urea cycle disorders in granules and oral solution forms, Granupas for multidrug-resistant tuberculosis, and Amsalyo (amsacrine). The company improves formulations of existing molecules, develops new presentations for specific age groups (neonates, children, adults), and sells directly to hospitals and pharmacies across France, Turkey, Spain, Italy, the UK, and Benelux while using distributors in other global markets.

Product overview

Lucane Pharma is a pharmaceutical company specializing in the development and commercialization of medicines for rare diseases. The company operates as part of Eurocept Pharmaceuticals Holding and offers a portfolio of niche medicines including Xaluprine (mercaptopurine oral suspension for acute lymphocytic leukemia), Ucedane (carglumic acid for urea cycle disorders), Pheburane (sodium phenylbutyrate for urea cycle disorders), Granupas (para-aminosalicylic acid for multidrug-resistant tuberculosis), and Amsalyo (amsacrine for infusion). Lucane Pharma improves formulations of existing products, develops new presentations fulfilling specific needs, and improves global accessibility of its products through direct presence in France, Turkey, Spain, Italy, United Kingdom, Benelux, and via distributors globally. The company is actively engaged in the development of 9 products for very rare disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • Xaluprine Brand-name mercaptopurine oral suspension indicated for the treatment of acute lymphocytic leukemia. Belongs to the cytotoxics (chemotherapy) group that works by preventing cancer cells from multiplying, and was specifically designed to facilitate dosing in specific age groups.
  • Ucedane An alternative version of carglumic acid with notable differences from the original, used in the treatment of urea cycle disorders (UCDs).
  • Pheburane An alternative version of sodium phenylbutyrate with notable differences from the original, used in the treatment of urea cycle disorders (UCDs). Available in granules and oral solution forms.
  • Granupas Brand-name para-aminosalicylic acid, a proven molecule used as part of an appropriate combination regimen for multidrug-resistant tuberculosis, which is rare in the EU today.
  • Amsalyo Brand-name amsacrine powder for solution for infusion. Belongs to the cytotoxics (chemotherapy) group that works by preventing cancer cells from multiplying.

Companies that use Lucane Pharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Lucane Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lucane Pharma partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Lucane Pharma competitors and assessment

Company assessment

Direct peers

  • Recordati Rare Diseases: Specialty pharmaceutical division of Recordati focused on rare diseases with direct presence across Europe; directly comparable in commercial model, therapeutic focus (rare metabolic and endocrine disorders), and EMA-anchored portfolio strategy.
  • BioMarin Pharmaceutical: Global rare-disease biotech with multiple EMA-approved products for very rare metabolic disorders; comparable in orphan-drug commercial focus and concentration on small-population specialty therapeutics.
  • Swedish Orphan Biovitrum (Sobi): Public rare-disease specialty pharma headquartered in Europe, with a portfolio centered on niche metabolic, hematology, and immunology indications — directly comparable in orphan-drug strategy, EU regulatory focus, and reformulation/repositioning approach.
  • Kyowa Kirin International: European specialty pharma arm of Kyowa Kirin focused on rare diseases and specialty therapeutics with strong EU commercialization; comparable in orphan-drug portfolio strategy and direct presence in multiple EU countries.
  • Ultragenyx Pharmaceutical: Clinical-stage and commercial rare-disease biotech focused on metabolic and rare genetic disorders; comparable in orphan-drug regulatory pathway, small patient populations, and reformulation/repositioning of therapies.
  • Jazz Pharmaceuticals: Specialty pharma with a portfolio spanning rare oncology, neurology, and sleep disorders; comparable in niche-indication focus, EMA presence, and reformulation of existing molecules (e.g., oral suspension presentations).
  • Orphan Europe (Recordati Group): European rare-disease pharma (now part of Recordati) that develops and commercializes treatments for very rare disorders; highly comparable in mission, EMA orphan-drug portfolio, and small-population disease focus.

Broad incumbents

  • Chiesi Farmaceutici: European-headquartered specialty pharma with rare-disease and neonatology franchises; comparable in EU direct commercialization, focus on underserved pediatric/rare populations, and reformulation of established molecules.
  • Genzyme (Sanofi Rare Disease): Pioneering rare-disease franchise within Sanofi with deep expertise in metabolic disorders (e.g., enzyme replacement therapies); comparable in therapeutic area overlap (UCDs, metabolic conditions) but at global mega-cap scale.
  • Alexion (AstraZeneca Rare Disease): Established global rare-disease franchise within AstraZeneca, with multiple EMA-approved orphan drugs and direct European commercialization — overlaps in therapeutic areas and regulatory pathways, but operates at vastly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Lucane Pharma social profiles

Digital presence

Lucane Pharma compliance and trust

Trust signal

Compliance3 records

Lucane Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucane Pharma leadership team

Management profile

Number of profiles

Profiles9 records

Lucane Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Lucane Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucane Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucane Pharma

What does Lucane Pharma do?

Lucane Pharma develops, registers, and commercializes proprietary and licensed pharmaceutical products targeting rare disorders (orphan drugs). Its marketed portfolio includes Xaluprine for acute lymphocytic leukemia, Ucedane for urea cycle disorders (carglumic acid), Pheburane (sodium phenylbutyrate) for urea cycle disorders in granules and oral solution forms, Granupas for multidrug-resistant tuberculosis, and Amsalyo (amsacrine). The company improves formulations of existing molecules, develops new presentations for specific age groups (neonates, children, adults), and sells directly to hospitals and pharmacies across France, Turkey, Spain, Italy, the UK, and Benelux while using distributors in other global markets.

Is Lucane Pharma a public or private company?

Lucane Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Lucane Pharma founded?

Lucane Pharma was founded in 2009. It employs 1 to 10 people.

Where is Lucane Pharma based?

Lucane Pharma is headquartered in Paris, France, in the Europe region.

How does Lucane Pharma make money?

One revenue line is on record: pharmaceutical product sales.

Who are Lucane Pharma's main competitors?

Direct peers on record are Recordati Rare Diseases, BioMarin Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Kyowa Kirin International, Ultragenyx Pharmaceutical, Jazz Pharmaceuticals and Orphan Europe (Recordati Group). Broad incumbents are Chiesi Farmaceutici, Genzyme (Sanofi Rare Disease) and Alexion (AstraZeneca Rare Disease).

Does Lucane Pharma have an API?

No public API is recorded for Lucane Pharma.

What industry is Lucane Pharma in?

Lucane Pharma's product category is Orphan Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales